Eli Lilly's innovation and pipeline diversification support long-term growth, despite patent risks and competition. Read more ...

Revvity targets 2026 growth with multiomics, AI-powered base editing, NGS newborn screening, and immunotherapy advances.

The gene editing market is experiencing significant growth, with a projected annual growth rate (CAGR) of 16-18% in the coming years. This expansion is fueled by breakthroughs in gene-editing ...

Cathie Wood’s ARK Invest ETFs (exchange-traded funds) made a series of notable trades on Monday, December 1, according to ...

CRISPR technology, a revolutionary tool in genetic engineering, has empowered Lambert's iGEM team to tackle a significant health issue: Lyme disease, which affects nearly half a million Americans ...

To compete at iGEM, a sort of science Olympics, teens at a Georgia high school set their sights on finding a better way to ...

Instead of requiring personalized gene edits for each patient, the new approach could create a standardized method to use for many diseases. By Pam Belluck and Carl Zimmer Gene-editing therapies offer ...

Forbes contributors publish independent expert analyses and insights. Juergen Eckhardt leads Bayer’s impact investment unit, Leaps by Bayer. Dr. David Liu, pictured with former lab members Holly Rees ...

A major medical milestone took place in May 2025, when doctors at the Children’s Hospital of Philadelphia used CRISPR-based gene editing to treat a child with a rare genetic disorder. Unlike earlier ...

Urnov is a professor of molecular therapeutics at the University of California, Berkeley, and a director at its Innovative Genomics Institute. In May, news broke of a biomedical first: the on-demand ...

A new gene-editing technique enables the correction of multiple genetic mutations simultaneously, transforming the prospects for millions living with complex inherited diseases, such as cystic ...

In a step toward the wider use of gene editing, a treatment that uses Crispr successfully slashed high cholesterol levels in a small number of people. In a trial conducted by Swiss biotech company ...